Advanced Breast Cancer: Adding Abemaciclib to Fulvestrant Improves Survival

​ Updated results from MONARCH 2 report that adding abemaciclib (Verzenio ® , Eli Lilly) to fulvestrant (Faslodex ® , AstraZeneca) improves overall survival compared with fulvestrant alone in patients with endocrine-refractory hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. "Most patients with metastatic breast cancer have tumors that are HR-positive and are initially treated with endocrine therapy. Although endocrine therapy is an...
Continue reading

In Breast Cancer, Men Have Increased Mortality

Even after adjustment for undertreatment and differing clinical characteristics, men with breast cancer have higher mortality rates than women, report the authors of a nationwide cohort study. The researchers, who are from Vanderbilt University Medical Center in Nashville, Tennessee, analyzed data obtained from the National Cancer Database on 1,816,733 patients diagnosed with breast cancer between January 2004 and December 2014. The patient population included 16,025 men and 1,800,708 women. The...
Continue reading

​Poultry Consumption Linked to Cancer Risk

In addition to the known cancer risks associated with consumption of red and processed meats, a new study warns of an increased cancer risk from poultry. "The latest meta-analysis from the World Cancer Research Fund/American Institute for Cancer Research concluded that red meat was a probable cause and processed meat a convincing cause of colorectal cancer," write the researchers in their presentation abstract in the Journal of Epidemiology and Community Health , led by first author Anika Knüppe...
Continue reading

Proton Therapy for Breast Cancer With Rachel B. Jimenez, MD

While conventional radiation therapy can be effective for patients with breast cancer, it carries with it risk of damage to the heart and lungs. Proton beam radiotherapy, a specialized type of external beam radiation that precisely targets a tumor with high doses of radiation while minimizing damage to nearby tissue and critical organs, shows promise as an alternative for some patients. In a phase 2 study published recently in the Journal of Clinical Oncology , a team of researchers at Massachus...
Continue reading

Who Should Receive Breast Cancer Chemoprevention? USPSTF Updates Recommendations

The United States Preventive Services Task Force (USPSTF) has issued an updated recommendation statement on the use of medication to reduce the risk of breast cancer. Breast cancer is the most frequently occurring nonskin cancer and the second most common cause of cancer-related death among women, but for whom is the reduction in cancer risk worth the potential adverse effects of the medications? The guidelines, published in JAMA , recommend the use of risk-reducing medications for asymptomatic ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.